{"id":"allogenic-mscs","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Immunogenicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Allogeneic MSCs are multipotent stromal cells derived from donor sources that migrate to damaged tissues and modulate the immune response through paracrine signaling, reducing inflammation and promoting endogenous repair mechanisms. These cells can differentiate into various cell types and secrete bioactive molecules including IL-10, TGF-β, and other factors that suppress pro-inflammatory responses and support tissue regeneration.","oneSentence":"Allogeneic mesenchymal stem cells (MSCs) exert immunomodulatory and regenerative effects by secreting anti-inflammatory cytokines and promoting tissue repair.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:26.156Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Graft-versus-host disease (GVHD)"},{"name":"Tissue repair and regeneration"}]},"trialDetails":[{"nctId":"NCT07498218","phase":"PHASE1","title":"Phase 1 Study of VELGRAFT, a Living Cellular Construct, in the Management of Chronic Diabetic Foot Ulcers Which Have Attained Granulation Tissue","status":"NOT_YET_RECRUITING","sponsor":"Ayu, Inc.","startDate":"2026-03-02","conditions":"Diabetic Foot Ulcer (DFU), Granulation of Chronic Diabetic Wounds","enrollment":24},{"nctId":"NCT07238062","phase":"","title":"\"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy.\"","status":"TEMPORARILY_NOT_AVAILABLE","sponsor":"Hope Biosciences Research Foundation","startDate":"","conditions":"Multiple System Atrophy","enrollment":""},{"nctId":"NCT04314661","phase":"PHASE1, PHASE2","title":"Mesenchymal Stem Cell Therapy (MSCs) and Conditioned Medium Therapy for Osteoartrithis","status":"COMPLETED","sponsor":"PT. Prodia Stem Cell Indonesia","startDate":"2020-08-03","conditions":"Osteoarthritis, Knee","enrollment":31},{"nctId":"NCT04357600","phase":"PHASE1, PHASE2","title":"Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B","status":"ENROLLING_BY_INVITATION","sponsor":"PT. Prodia Stem Cell Indonesia","startDate":"2018-05-17","conditions":"Liver Cirrhoses","enrollment":12},{"nctId":"NCT04328714","phase":"PHASE1","title":"Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease","status":"TERMINATED","sponsor":"Edwin Horwitz","startDate":"2021-12-02","conditions":"Acute Leukemia, Myelodysplastic Syndromes","enrollment":4},{"nctId":"NCT07396155","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial","status":"RECRUITING","sponsor":"PT. Prodia Stem Cell Indonesia","startDate":"2026-07-01","conditions":"Diabetic Nephropathy Type 2","enrollment":10},{"nctId":"NCT07304440","phase":"PHASE1, PHASE2","title":"Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study","status":"RECRUITING","sponsor":"Adia Med of Winter Park LLC","startDate":"2026-01-12","conditions":"Autism Spectrum Disorder, Autism, ASD","enrollment":100},{"nctId":"NCT02633163","phase":"PHASE2","title":"Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2018-11-18","conditions":"Systemic Lupus Erythematosus","enrollment":81},{"nctId":"NCT05553132","phase":"PHASE1","title":"A Study of REcycled CartiLage Auto/Allo IMplantation to Treat and Repair Focal Hip Cartilage Defects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daniel B. F. Saris","startDate":"2023-08-08","conditions":"Cartilage Defect","enrollment":15},{"nctId":"NCT06001853","phase":"PHASE2","title":"Allogeneic BM-MSC's in Patients With Lumbar Facet Arthropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-11-03","conditions":"Facet-Mediated Low Back Pain","enrollment":40},{"nctId":"NCT07329569","phase":"PHASE2","title":"Treatment of Severe Ocular Chemical Burns by Subconjunctival Injection of Allogeneic Mesenchymal Stem Cells: An Open-Label, Single-Arm, Multicenter Phase II Trial","status":"NOT_YET_RECRUITING","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2026-03","conditions":"Chemical Burns, Ocular Burns","enrollment":21},{"nctId":"NCT05491681","phase":"PHASE1","title":"AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial","status":"WITHDRAWN","sponsor":"BioCardia, Inc.","startDate":"2026-01-04","conditions":"ARDS, Human","enrollment":""},{"nctId":"NCT02962661","phase":"PHASE1","title":"Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-18","conditions":"Cardiomyopathy, Heart Failure, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":72},{"nctId":"NCT07240987","phase":"PHASE1, PHASE2","title":"Mesenchymal Stem Cells for Chronic Kidney Diseases","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Air Force Medicial University","startDate":"2026-01-01","conditions":"Kidney Disease, Chronic, Diabetic Kidney Disease (DKD), Hypertensive Nephropathy","enrollment":32},{"nctId":"NCT06328712","phase":"PHASE1","title":"Evaluate the Safety and Efficacy of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A","status":"COMPLETED","sponsor":"ENCell","startDate":"2024-05-30","conditions":"Charcot-Marie-Tooth Disease Type 1A","enrollment":6},{"nctId":"NCT05705024","phase":"PHASE2","title":"Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2023-09-29","conditions":"Corneal Ulcer","enrollment":38},{"nctId":"NCT05925608","phase":"PHASE1, PHASE2","title":"Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioCardia, Inc.","startDate":"2023-08-23","conditions":"Heart Failure, Systolic","enrollment":39},{"nctId":"NCT05838092","phase":"PHASE3","title":"Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)","status":"ACTIVE_NOT_RECRUITING","sponsor":"RHEACELL GmbH & Co. KG","startDate":"2023-10-18","conditions":"Epidermolysis Bullosa","enrollment":9},{"nctId":"NCT05464381","phase":"PHASE3","title":"Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)","status":"ACTIVE_NOT_RECRUITING","sponsor":"RHEACELL GmbH & Co. KG","startDate":"2023-06-13","conditions":"Epidermolysis Bullosa","enrollment":91},{"nctId":"NCT06549686","phase":"PHASE3","title":"A Phase III Study of CLS2901C in Patients With Osteoarthritis of the Knee","status":"RECRUITING","sponsor":"CellSeed Inc.","startDate":"2023-10-20","conditions":"Osteoarthritis of the Knee","enrollment":96},{"nctId":"NCT05559801","phase":"PHASE1, PHASE2","title":"Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)","status":"NOT_YET_RECRUITING","sponsor":"Emory University","startDate":"2026-02","conditions":"Osteogenesis Imperfecta, Osteogenesis Imperfecta Type III","enrollment":12},{"nctId":"NCT05789394","phase":"PHASE1","title":"Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-06-16","conditions":"Recurrent Glioblastoma, IDH-Wildtype, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Astrocytoma, Grade IV","enrollment":20},{"nctId":"NCT06489028","phase":"PHASE3","title":"Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)","status":"ACTIVE_NOT_RECRUITING","sponsor":"RHEACELL GmbH & Co. KG","startDate":"2024-12-26","conditions":"Venous Leg Ulcer","enrollment":250},{"nctId":"NCT03737461","phase":"PHASE2, PHASE3","title":"Efficacy of Intradiscal Injection of BM-MSC in Subjects With Chronic Low Back Pain (LBP) Due to Lumbar Degenerative Disc Disease (DDD) Unresponsive","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2019-02-18","conditions":"Recurrent Low Back Pain, Degenerative Disc Disease (DDD)","enrollment":113},{"nctId":"NCT04362189","phase":"PHASE2","title":"Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19","status":"TERMINATED","sponsor":"Hope Biosciences Research Foundation","startDate":"2020-06-30","conditions":"COVID-19","enrollment":48},{"nctId":"NCT02685098","phase":"PHASE1","title":"A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation","status":"COMPLETED","sponsor":"Indiana University","startDate":"2017-01-23","conditions":"Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease","enrollment":81},{"nctId":"NCT07106229","phase":"PHASE3","title":"A Study to Investigate the Effectiveness, Safety, and Tolerability of MAG200 Solution for Intra-articular Injection Compared With Placebo in Participants Aged 35 to 75 Years of Age With Symptomatic Osteoarthritis of the Knee.","status":"NOT_YET_RECRUITING","sponsor":"Magellan Stem Cells","startDate":"2025-11","conditions":"Knee Osteoarthristis","enrollment":573},{"nctId":"NCT03211793","phase":"PHASE1, PHASE2","title":"Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2021-10-06","conditions":"Systemic Sclerosis, Digital Ulcer","enrollment":20},{"nctId":"NCT05854641","phase":"PHASE4","title":"Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease","status":"RECRUITING","sponsor":"Cell Biopeutics Resources Sdn Bhd","startDate":"2024-01-01","conditions":"Critical Limb Ischemia, Peripheral Arterial Disease","enrollment":10},{"nctId":"NCT05854615","phase":"PHASE4","title":"Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease","status":"RECRUITING","sponsor":"Cell Biopeutics Resources Sdn Bhd","startDate":"2024-01-01","conditions":"Critical Limb Ischemia, Buerger's Disease","enrollment":3},{"nctId":"NCT04869397","phase":"PHASE2","title":"Treatment of Respiratory Complications Associated With COVID-19 Using Umbilical Cord Mesenchymal Stromal Cells","status":"TERMINATED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2021-06-14","conditions":"Covid19","enrollment":19},{"nctId":"NCT04776239","phase":"PHASE1, PHASE2","title":"Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)","status":"COMPLETED","sponsor":"Joshua M Hare","startDate":"2021-08-16","conditions":"Diabetes Mellitus, Ischemic Heart Disease","enrollment":26},{"nctId":"NCT07146087","phase":"EARLY_PHASE1","title":"Allogeneic Mesenchymal Stem Cell-Derived Exosome Therapy for Progressive Multiple Sclerosis","status":"SUSPENDED","sponsor":"Biocells Medical","startDate":"2020-07-01","conditions":"Multiple Sclerosis","enrollment":20},{"nctId":"NCT07058025","phase":"PHASE2","title":"Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants","status":"NOT_YET_RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2025-10-01","conditions":"Bronchopulmonary Dysplasia (BPD), ELGAN (22-28SA)","enrollment":168},{"nctId":"NCT06886646","phase":"PHASE2","title":"Allogeneic Umbilical Cord Mesenchymal Stromal Cells for the Treatment of Chronic Antibody-Mediated Rejection in Kidney Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-09-15","conditions":"Chronic Antibody-mediated Rejection (cABMR)","enrollment":22},{"nctId":"NCT03522545","phase":"PHASE1","title":"Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2022-04-20","conditions":"Treatment-resistant Bipolar Depression","enrollment":30},{"nctId":"NCT06981338","phase":"PHASE1, PHASE2","title":"Guttmann NeuroRecovery - Viability, Safety, and Efficacy of Intrathecal Wharton's Jelly Mesenchymal Stem Cells and Transcutaneous Spinal Cord Stimulation in Chronic Spinal Cord Injury Rehabilitation","status":"NOT_YET_RECRUITING","sponsor":"Institut Guttmann","startDate":"2025-09-01","conditions":"Spinal Cord Injuries (SCI), Spinal Cord Injury, Traumatic Spinal Cord Injuries","enrollment":10},{"nctId":"NCT05039411","phase":"PHASE1","title":"Safety of Allogeneic Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) to Treat Perianal Fistulas w/ Crohn's Disease","status":"RECRUITING","sponsor":"CryoCord Sdn Bhd","startDate":"2022-03-01","conditions":"Perianal Fistula Due to Crohn's Disease, Fistula in Ano","enrollment":5},{"nctId":"NCT06813027","phase":"PHASE1","title":"Use of Allogeneic Extracellular Secretomes (EV)Derived From Umbilical Cord Mesenchymal Stromal Cells: a Phase I Open-label Safety Trial.","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Jordan","startDate":"2023-01-01","conditions":"Vitiligo","enrollment":13},{"nctId":"NCT04447833","phase":"PHASE1","title":"Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Uppsala University","startDate":"2020-06-17","conditions":"ARDS, Human, COVID","enrollment":7},{"nctId":"NCT06817616","phase":"NA","title":"Arthroscopic Rotator Cuff Repair with UC-MSCs for Large to Massive Tears","status":"RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2025-01-17","conditions":"Rotator Cuff Disease","enrollment":15},{"nctId":"NCT05165628","phase":"PHASE1","title":"Safety, Tolerability and Efficacy of CYP-006TK in Adults with Diabetic Foot Ulcers","status":"COMPLETED","sponsor":"Cynata Therapeutics Limited","startDate":"2022-01-04","conditions":"Diabetic Foot Ulcer, Cutaneous Ulcer","enrollment":30},{"nctId":"NCT06293950","phase":"PHASE1","title":"Allogeneic Wharton Jelly Mesenchymal Stromal Cell (WJMSC) for Treatment of Autism","status":"RECRUITING","sponsor":"University of Jordan","startDate":"2022-03-09","conditions":"Autism","enrollment":14},{"nctId":"NCT05333029","phase":"PHASE2","title":"Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD","status":"WITHDRAWN","sponsor":"Molly Gallogly","startDate":"2024-10-01","conditions":"Graft Versus Host Disease","enrollment":""},{"nctId":"NCT04410731","phase":"PHASE1","title":"Allogeneic BM-MSCs in Patients with Lumbar Facet Arthropathy","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2020-04-28","conditions":"Facet-Mediated Low Back Pain","enrollment":10},{"nctId":"NCT06078059","phase":"NA","title":"Mechanisms of Treatment Effects Using Cultured, Allogeneic Mesenchymal Stromal Stem Cells (MSCs) in Knee Osteoarthritis","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2022-11-01","conditions":"Osteoarthritis, Knee","enrollment":30},{"nctId":"NCT05969275","phase":"PHASE2","title":"Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2024-02-14","conditions":"Septic Shock, Sepsis, Pathologic Processes","enrollment":296},{"nctId":"NCT05086939","phase":"PHASE3","title":"Multicenter Clinical Trial Comparing Treatment with Allogeneic Mesenchymal Cells Versus Autologous Mesenchymal Cells and Versus Active Control with Hyaluronic Acid in Patients with Knee Osteoarthritis.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León","startDate":"2021-05-26","conditions":"Knee Osteoarthritis","enrollment":124},{"nctId":"NCT05286255","phase":"PHASE1","title":"Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias","status":"WITHDRAWN","sponsor":"Medical University of South Carolina","startDate":"2024-10-01","conditions":"COVID-19 Pneumonia, Viral Pneumonia","enrollment":""},{"nctId":"NCT02582775","phase":"PHASE2","title":"MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2016-03","conditions":"Epidermolysis Bullosa","enrollment":17},{"nctId":"NCT06574581","phase":"PHASE1, PHASE2","title":"ADSCs Therapy in Patients With CTD-ILD","status":"RECRUITING","sponsor":"China Medical University Hospital","startDate":"2024-08-20","conditions":"Connective Tissue Diseases, Interstitial Lung Disease","enrollment":16},{"nctId":"NCT02846883","phase":"PHASE1","title":"Safety and Efficacy of Allogeneic MSCs in Promoting T-regulatory Cells in Patients With Small Abdominal Aortic Aneurysms","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2016-12-05","conditions":"Abdominal Aortic Aneurysm","enrollment":28},{"nctId":"NCT04506073","phase":"PHASE2","title":"Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2020-11-09","conditions":"Parkinson's Disease","enrollment":45},{"nctId":"NCT05933434","phase":"PHASE1, PHASE2","title":"Allogenic Mesenchymal Stem Cell Intraarticular Injection for Knee Osteoarthritis Therapy","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2024-03-07","conditions":"Knee Osteoarthritis","enrollment":80},{"nctId":"NCT03356821","phase":"PHASE1, PHASE2","title":"Perinatal Arterial Stroke Treated With Stromal Cells Intranasally","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2020-02-11","conditions":"Perinatal Arterial Ischemic Stroke, Neonatal Stroke","enrollment":10},{"nctId":"NCT02150551","phase":"PHASE1","title":"Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Catherine Bollard","startDate":"2018-06-07","conditions":"Inflammatory Bowel Diseases","enrollment":1},{"nctId":"NCT02213705","phase":"PHASE1, PHASE2","title":"Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-05-06","conditions":"SYSTEMIC SCLERODERMA, ALLOGENEIC MESENCHYMAL STEM CELLS, ADULT","enrollment":20},{"nctId":"NCT06074783","phase":"PHASE1, PHASE2","title":"A Study of Human Allogeneic Bone-marrow Derived Mesenchymal Stromal Cell Product (StromaForte) in Patients With Musculoskeletal Injuries and/or Degeneration","status":"RECRUITING","sponsor":"Cellcolabs Clinical LTD.","startDate":"2023-10-20","conditions":"Musculoskeletal Injury","enrollment":30},{"nctId":"NCT04992247","phase":"PHASE2","title":"Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 \"Long Haul\" Pulmonary Compromise","status":"WITHDRAWN","sponsor":"Sorrento Therapeutics, Inc.","startDate":"2024-02","conditions":"Covid19","enrollment":""},{"nctId":"NCT04961658","phase":"PHASE1","title":"Advanced Mesenchymal Enhanced Cell THerapY for SepTic Patients","status":"TERMINATED","sponsor":"Northern Therapeutics","startDate":"2021-08-11","conditions":"Septic Shock","enrollment":11},{"nctId":"NCT03635450","phase":"PHASE1","title":"Study of hCT-MSC in Newborn Infants With Moderate or Severe HIE","status":"COMPLETED","sponsor":"Joanne Kurtzberg, MD","startDate":"2018-12-27","conditions":"Moderate to Severe Hypoxic-ischemic Encephalopathy","enrollment":6},{"nctId":"NCT01033552","phase":"PHASE1, PHASE2","title":"Biochemical Correction of Severe EB by Allo HSCT and \"Off-the-shelf\" MSCs","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2010-01","conditions":"Epidermolysis Bullosa","enrollment":32},{"nctId":"NCT06328725","phase":"PHASE1, PHASE2","title":"Evaluate the Efficacy and Safety of EN001 in Patients With Duchenne Muscular Dystrophy","status":"NOT_YET_RECRUITING","sponsor":"ENCell","startDate":"2024-03","conditions":"Duchenne Muscular Dystrophy","enrollment":88},{"nctId":"NCT06304025","phase":"PHASE1, PHASE2","title":"Sequential Administration of WJ-MSCs for the Treatment of GvHD Refractory to Second Line Treatment","status":"NOT_YET_RECRUITING","sponsor":"Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle","startDate":"2024-06","conditions":"Graft Versus Host Disease","enrollment":10},{"nctId":"NCT06231771","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Stem Cells for Diabetic Foot Ulcer","status":"NOT_YET_RECRUITING","sponsor":"Supergenics Life Science Sdn. Bhd.","startDate":"2024-05","conditions":"Diabetic Foot Ulcer","enrollment":22},{"nctId":"NCT04361942","phase":"PHASE2","title":"Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stem Cells","status":"COMPLETED","sponsor":"Red de Terapia Celular","startDate":"2020-05-01","conditions":"COVID-19 Pneumonia","enrollment":24},{"nctId":"NCT05016011","phase":"PHASE2","title":"Efficacy of Allogeneic UCMSCs for Treating Large Defects Knee Injury","status":"COMPLETED","sponsor":"Cytopeutics Sdn. Bhd.","startDate":"2020-07-01","conditions":"Osteoarthritis, Knee","enrollment":28},{"nctId":"NCT06171906","phase":"PHASE4","title":"Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation","status":"NOT_YET_RECRUITING","sponsor":"ShiCang Yu","startDate":"2024-01-01","conditions":"MSC","enrollment":68},{"nctId":"NCT05346120","phase":"PHASE2","title":"Post-Acute COVID-19, Inflammation, and Depression","status":"WITHDRAWN","sponsor":"Sean Savitz","startDate":"2022-05-25","conditions":"Post COVID -19 Depression","enrollment":""},{"nctId":"NCT02709343","phase":"PHASE2","title":"Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction","status":"COMPLETED","sponsor":"The University of Queensland","startDate":"2017-04-21","conditions":"Chronic Lung Allograft Dysfunction (CLAD)","enrollment":64},{"nctId":"NCT02611167","phase":"PHASE1","title":"Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2017-11-01","conditions":"Parkinson's Disease","enrollment":20},{"nctId":"NCT06063590","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Allogenic Bone-Marrow Mesenchymal Stromal Cell Product StromaForte in Aging Frailty Patients","status":"UNKNOWN","sponsor":"Cellcolabs Clinical SPV Limited","startDate":"2023-11-28","conditions":"Aging Frailty","enrollment":12},{"nctId":"NCT06103396","phase":"PHASE1, PHASE2","title":"Treatment of Nonunion Fractures With Mesenchymal Stromal Cells (MSCs)","status":"UNKNOWN","sponsor":"Instituto Venezolano de Investigaciones Cientificas","startDate":"2018-01-30","conditions":"Pseudoarthrosis of Bone, Pseudarthrosis, Non Union Fracture","enrollment":30},{"nctId":"NCT06103409","phase":"PHASE1, PHASE2","title":"MSCs for the Treatment of Burn Wounds","status":"UNKNOWN","sponsor":"Instituto Venezolano de Investigaciones Cientificas","startDate":"2021-06-30","conditions":"Burn Wound, Second- or Third-degree Burn","enrollment":50},{"nctId":"NCT04034316","phase":"PHASE2","title":"Reduce Immunosuppression With Atmp in NS ChildrEn","status":"COMPLETED","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2018-11-02","conditions":"Nephrotic Syndrome in Children, Steroid-Dependent Nephrotic Syndrome, Idiopathic Nephrotic Syndrome","enrollment":20},{"nctId":"NCT03265613","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis","status":"COMPLETED","sponsor":"Guangdong Provincial Hospital of Traditional Chinese Medicine","startDate":"2017-09-24","conditions":"Mesenchymal Stromal Cells, Psoriasis, Drug Toxicity","enrollment":7},{"nctId":"NCT03392311","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis","status":"COMPLETED","sponsor":"Guangdong Provincial Hospital of Traditional Chinese Medicine","startDate":"2019-07-23","conditions":"Mesenchymal Stromal Cells, Psoriasis, Drug Effect","enrollment":8},{"nctId":"NCT04785027","phase":"PHASE1, PHASE2","title":"Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis","status":"UNKNOWN","sponsor":"Guangdong Provincial Hospital of Traditional Chinese Medicine","startDate":"2021-03-17","conditions":"Traditional Chinese Medicine, Drug Effect, Drug Safety","enrollment":16},{"nctId":"NCT05962762","phase":"PHASE1","title":"Safety and Tolerance of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Ankylosing Spondylitis","status":"NOT_YET_RECRUITING","sponsor":"Asia Cell Therapeutics (Shanghai) Co., Ltd.","startDate":"2023-08-30","conditions":"Ankylosing Spondylitis","enrollment":9},{"nctId":"NCT05983627","phase":"PHASE1","title":"Safety and Tolerance of Umbilical Cord Mesenchymal Stem Cells in Patients With Acute Respiratory Distress Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Asia Cell Therapeutics (Shanghai) Co., Ltd.","startDate":"2023-08-30","conditions":"Acute Respiratory Distress Syndrome","enrollment":9},{"nctId":"NCT05975892","phase":"PHASE1, PHASE2","title":"Transplantation of Bone Marrow Mesenchymal Stromal Cells for Periodontal Regeneration","status":"UNKNOWN","sponsor":"Instituto Venezolano de Investigaciones Cientificas","startDate":"2018-08-30","conditions":"Chronic Periodontal Disease, Aggressive Periodontitis","enrollment":30},{"nctId":"NCT05948982","phase":"PHASE1, PHASE2","title":"Safety of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Decompensated Hepatitis B Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Asia Cell Therapeutics (Shanghai) Co., Ltd.","startDate":"2023-07-30","conditions":"Decompensated Liver Cirrhosis","enrollment":18},{"nctId":"NCT03929120","phase":"PHASE1","title":"Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-11-05","conditions":"Interstitial Lung Disease, Connective Tissue Diseases","enrollment":10},{"nctId":"NCT02866721","phase":"PHASE1","title":"Safety and Tolerability Study of Allogeneic Mesenchymal Stem Cell Infusion in Adults With Cystic Fibrosis","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2016-08","conditions":"Cystic Fibrosis","enrollment":14},{"nctId":"NCT05407766","phase":"PHASE1","title":"Mesenchymal Stem Cells (MSCs) for Perianal Fistula","status":"WITHDRAWN","sponsor":"Ossium Health, Inc.","startDate":"2022-08","conditions":"Rectal Fistula","enrollment":""},{"nctId":"NCT05443464","phase":"PHASE1","title":"Mesenchymal Stem Cells (MSCs) for Steroid Refractory Acute GVHD (SR-aGVHD)","status":"WITHDRAWN","sponsor":"Ossium Health, Inc.","startDate":"2023-06-05","conditions":"GVHD,Acute","enrollment":""},{"nctId":"NCT05631444","phase":"PHASE1, PHASE2","title":"Bone Marrow Mononuclear Cells vs Mesenchymal Stem Cells in Diabetic Patients With Chronic Limb Ischemia","status":"COMPLETED","sponsor":"Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle","startDate":"2019-01-01","conditions":"Chronic Limb-threatening Ischemia, Diabetes Mellitus","enrollment":24},{"nctId":"NCT03059355","phase":"PHASE1, PHASE2","title":"Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.","status":"TERMINATED","sponsor":"Joshua M Hare","startDate":"2018-04-12","conditions":"Endothelial Dysfunction, Metabolic Syndrome, Chronic Inflammation","enrollment":14},{"nctId":"NCT05578508","phase":"PHASE1","title":"Stem Cells for the Treatment of Pouchitis","status":"WITHDRAWN","sponsor":"The Cleveland Clinic","startDate":"2022-04","conditions":"Pouchitis, Crohn's Disease, Ulcerative Colitis Chronic","enrollment":""},{"nctId":"NCT04340609","phase":"PHASE1, PHASE2","title":"Stem Cell in Acute Myocardial Infarction","status":"COMPLETED","sponsor":"PT. Prodia Stem Cell Indonesia","startDate":"2019-03-11","conditions":"Acute Myocardial Infarction","enrollment":4},{"nctId":"NCT02408432","phase":"PHASE1","title":"Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-01-11","conditions":"Cardiomyopathy, Heart Failure","enrollment":7},{"nctId":"NCT04073472","phase":"PHASE1","title":"Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in Crohn's","status":"WITHDRAWN","sponsor":"The Cleveland Clinic","startDate":"2021-06-01","conditions":"Crohn's Disease, Fistula, Anal Fistula","enrollment":""},{"nctId":"NCT04548583","phase":"PHASE1, PHASE2","title":"Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis","status":"UNKNOWN","sponsor":"The Cleveland Clinic","startDate":"2020-11-04","conditions":"Crohn Colitis","enrollment":24},{"nctId":"NCT04543994","phase":"PHASE1, PHASE2","title":"Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)","status":"UNKNOWN","sponsor":"The Cleveland Clinic","startDate":"2020-11-10","conditions":"Ulcerative Colitis","enrollment":24},{"nctId":"NCT00136903","phase":"PHASE2","title":"Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)","status":"COMPLETED","sponsor":"Mesoblast, Inc.","startDate":"2005-04-27","conditions":"Graft Vs Host Disease","enrollment":32},{"nctId":"NCT04377334","phase":"PHASE2","title":"Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS)","status":"UNKNOWN","sponsor":"University Hospital Tuebingen","startDate":"2022-05","conditions":"ARDS, COVID-19","enrollment":40},{"nctId":"NCT04445220","phase":"PHASE1, PHASE2","title":"A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy","status":"UNKNOWN","sponsor":"Sentien Biotechnologies, Inc.","startDate":"2020-11-19","conditions":"COVID-19, Acute Kidney Injury, Sepsis","enrollment":22},{"nctId":"NCT04194671","phase":"PHASE1, PHASE2","title":"Clinical Trial of Mesenchymal Stem Cells in the Treatment of Severe Acute Kidney Injury","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2021-12-31","conditions":"Acute Kidney Injury, Mesenchymal Stem Cells","enrollment":80},{"nctId":"NCT04728698","phase":"PHASE2","title":"Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress","status":"WITHDRAWN","sponsor":"Sorrento Therapeutics, Inc.","startDate":"2021-03","conditions":"Covid19, ARDS","enrollment":""},{"nctId":"NCT04549285","phase":"PHASE1","title":"Infusions of Mesenchymal Stromal Cells in Children With Multisystem Inflammatory Syndrome","status":"WITHDRAWN","sponsor":"Joanne Kurtzberg, MD","startDate":"2021-03-12","conditions":"Multisystem Inflammatory Syndrome in Children","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":64,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Allogenic MSCs","genericName":"Allogenic MSCs","companyName":"Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León","companyId":"fundaci-n-instituto-de-estudios-de-ciencias-de-la-salud-de-castilla-y-le-n","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Allogeneic mesenchymal stem cells (MSCs) exert immunomodulatory and regenerative effects by secreting anti-inflammatory cytokines and promoting tissue repair. Used for Graft-versus-host disease (GVHD), Tissue repair and regeneration.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}